Is Neuronetics, Inc. overvalued or undervalued?

As of 6 November 2018, the valuation grade for Neuronetics, Inc. has moved from does not qualify to risky. The company is currently assessed as overvalued given its significant negative financial metrics. Key ratios include a Price to Book Value of 6.91, an EV to EBITDA of -7.93, and a ROE of -122.96%. In comparison to its peers, Neuronetics shows a P/E ratio of -5.27, while Delcath Systems, Inc. also reflects a risky valuation with a P/E of -509.51, indicating that both companies are struggling financially. Other peers like Sensus Healthcare, Inc. are categorized as expensive with a P/E of 44.22, further highlighting Neuronetics' unfavorable position in the market. Overall, the combination of these metrics suggests that Neuronetics is overvalued relative to its current financial performance and peer comparisons.